Technical Analysis for ADVM - Adverum Biotechnologies, Inc.

Grade Last Price % Change Price Change
D 12.83 2.48% 0.31
ADVM closed up 2.48 percent on Friday, February 26, 2021, on 1.14 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Mar 10
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical ADVM trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 20 DMA Bearish 2.48%
Fell Below 50 DMA Bearish 2.48%
20 DMA Support Bullish -3.46%
Bullish Engulfing Bullish -3.75%
Crossed Above 20 DMA Bullish -3.75%
Crossed Above 50 DMA Bullish -3.75%
Expansion Pivot Buy Setup Bullish Swing Setup -3.75%
Older End-of-Day Signals for ADVM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Adverum Biotechnologies, Inc. Description

Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Gene Therapy Macular Degeneration Related Macular Degeneration Genetic Disease Retina Wet Age Related Macular Degeneration Rare Genetic Disease Gene Therapy Of The Human Retina Gene Therapy Products Regeneron Adverum Biotechnologies Retinoschisis

Is ADVM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 26.98
52 Week Low 7.36
Average Volume 922,355
200-Day Moving Average 14.85
50-Day Moving Average 12.69
20-Day Moving Average 13.27
10-Day Moving Average 13.03
Average True Range 0.82
ADX 12.91
+DI 21.48
-DI 25.37
Chandelier Exit (Long, 3 ATRs ) 12.15
Chandelier Exit (Short, 3 ATRs ) 14.29
Upper Bollinger Band 14.44
Lower Bollinger Band 12.09
Percent B (%b) 0.31
BandWidth 17.75
MACD Line 0.02
MACD Signal Line 0.13
MACD Histogram -0.1151
Fundamentals Value
Market Cap 1.25 Billion
Num Shares 97.3 Million
EPS -1.05
Price-to-Earnings (P/E) Ratio -12.27
Price-to-Sales 3419.85
Price-to-Book 2.96
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.31
Resistance 3 (R3) 14.20 13.60 14.07
Resistance 2 (R2) 13.60 13.22 13.65 13.98
Resistance 1 (R1) 13.21 12.98 13.40 13.32 13.90
Pivot Point 12.61 12.61 12.70 12.66 12.61
Support 1 (S1) 12.22 12.23 12.42 12.34 11.76
Support 2 (S2) 11.62 11.99 11.67 11.68
Support 3 (S3) 11.23 11.62 11.59
Support 4 (S4) 11.35